STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma
ALK-positive Anaplastic Large Cell Lymphoma (ALK+ ALCL) is a rare yet aggressive T-cell lymphoma, most often characterized by the NPM1::ALK fusion. Because few somatic variants have been identified in ALK+ ALCL, we conducted paired whole-exome sequencing of patient tumors with matched normal tissue. Compared with previous studies, we identified a higher frequency of mutations in cohesin complex genes, mostly STAG2 variants (6/16) predicted to impair protein function. Immunohistochemistry confirmed loss of STAG2 in additional patient tumor samples. Using an original model of NPM1::ALK-driven lymphomagenesis that recapitulates early steps of ALK-driven transformation initiated in primary T lymphocytes, we demonstrated that STAG2 defect accelerates oncogenesis, enhancing early cell proliferation of ALK-positive cells. Single-cell RNA-seq revealed that STAG2 depletion accelerates the early acquisition of the major ALK+ ALCL hallmarks and concomitantly reduces the oncogene-induced senescence signature. Despite higher ALK expression and robust cell transformation, STAG2 depletion resulted in the attenuation of the global ALK+ ALCL transcriptional program. Importantly, STAG2 expression was found decreased upon NPM1::ALK induction, indicating intrinsic downregulation during transformation even without genomic mutations. We also successfully identified STAG2-low/ALK-high cells in both patient-derived tumors and PDX models. Functionally, STAG2-depleted cells exhibit increased cell adhesion and migration, alongside constitutive YAP1 activation and upregulation of adhesion molecule such as ALCAM and CD44 but also increased PD-L1. Overall, our findings reveal that STAG2 loss plays a key role during the earliest stages of ALK+ ALCL lymphomagenesis by promoting cell tolerance to NPM1::ALK expression and increasing permissiveness to malignant transformation while also impacting cell adhesion, migration.
Authors
- Erika Brunet (ORCID: https://orcid.org/0000-0002-1726-4673)
- Vahid Asnafi
- Alexandre Boullé
- Josquin Moraly (ORCID: https://orcid.org/0000-0002-8551-9658)
- Bruno M. Tesson (ORCID: https://orcid.org/0009-0006-0700-0240)
- Laurence Lamant (ORCID: https://orcid.org/0000-0002-1123-7658)
- Layla Veleanu (ORCID: https://orcid.org/0000-0003-2505-4649)
- Nicolas Cagnard (ORCID: https://orcid.org/0000-0002-9051-1896)
- Fabienne Meggetto (ORCID: https://orcid.org/0000-0002-2610-0144)
- Marion Le Grand (ORCID: https://orcid.org/0000-0002-4910-1289)
- Leonardo Panunzi (ORCID: https://orcid.org/0000-0002-5770-7037)
- Thomas Mercher (ORCID: https://orcid.org/0000-0003-1552-087X)
- Patrick Revy (ORCID: https://orcid.org/0000-0003-0758-8022)
- Zakia Aid
- Maxime Heintzé (ORCID: https://orcid.org/0009-0004-9890-6851)
- Lucile Couronné (ORCID: https://orcid.org/0000-0002-1357-5482)
- Rosalie Borry (ORCID: https://orcid.org/0009-0007-9748-5428)
- Carine Giovannangeli (ORCID: https://orcid.org/0000-0002-7715-8864)
- Ludovic Lhermitte (ORCID: https://orcid.org/0000-0003-2498-0376)
- Eddy Pasquier (ORCID: https://orcid.org/0000-0003-2824-5002)
- Emilia Puig Lombardi (ORCID: https://orcid.org/0000-0001-6387-8740)
- Alice Darchen
- Didier Surdez (ORCID: https://orcid.org/0000-0002-7118-7859)
- David Sibon (ORCID: https://orcid.org/0000-0002-9205-625X)
- Charlotte Degoutte
- Marie As (ORCID: https://orcid.org/0009-0003-3116-1747)
- Loélia Babin (ORCID: https://orcid.org/0000-0002-0188-6582)
- François Vilcot (ORCID: https://orcid.org/0009-0000-3009-9601)
- Elisa Fabiole
- Rania Sellami
- Kevin Muller
Institutions
- Délégation Paris 5 (FR)
- Hôpital Necker-Enfants Malades (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Institut Necker Enfants Malades (FR)
- Centre de Recherches en Cancérologie de Toulouse (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- University Hospital of Zurich (CH)
- The Lymphoma Academic Research Organisation (FR)
- Muséum national d'Histoire naturelle (FR)
- Universitätsklinik Balgrist (CH)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut des Maladies Génétiques Imagine (FR)
- Structure et Instabilité des Génomes (FR)
- Université Paris Descartes (FR)
Publication Details
- Journal
- Blood
- Published
- 2026-10-05
- DOI
- https://doi.org/10.1182/blood.2025032902
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00